Show simple item record

dc.contributor.authorBallard, Clive
dc.date.accessioned2020-08-25T12:52:29Z
dc.date.available2020-08-25T12:52:29Z
dc.date.issued2019
dc.identifier.citationFrölich L et al. Open-Label, Multicenter, Phase III Extension Study of Idalopirdine as Adjunctive to Donepezil for the Treatment of Mild-Moderate Alzheimer's Disease. J Alzheimers Dis. 2019;67(1):303-313. doi:10.3233/JAD-180595en_US
dc.identifier.pmid30636738
dc.identifier.doi10.3233/JAD-180595
dc.identifier.urihttps://rde.dspace-express.com/handle/11287/621393
dc.description.abstractThis open-label extension study evaluated the long-term safety and tolerability of idalopirdine 60 mg/day as adjunctive therapy in patients with mild-moderate Alzheimer's disease (AD). This extension study was a continuation of Studies 1 and 2 of the Phase III development program for idalopirdine and comprised a 28-week open-label treatment period ("OLEX") and a subsequent 24-week open-label treatment period with memantine ("MEMOLEX") in selected patients. The previous studies had shown no evidence of efficacy with idalopirdine as adjunctive treatment to donepezil but with good tolerability (of 1,791 patients randomized, 1,609 [90%] completed the double-blind studies). Of those, 1,463 patients (91%) entered the open-label extension study. During the 28-week OLEX period, the percentage of patients having treatment-emergent adverse events (TEAEs) ranged between 51% and 59% across the treatment groups originating from the lead-in studies. During the subsequent 24-week MEMOLEX period, 51% of the patients had TEAEs. Increases in liver enzymes (occurring in 1-3% of trial participants) were transient and no new safety signals were observed with longer term exposure. No consistent effects demonstrating benefits with idalopirdine were observed on efficacy parameters when patients transitioned to 60 mg in the extension study. Overall, idalopirdine was safe and well tolerated when added to donepezil, and when memantine was added to a prior combination of idalopirdine and donepezil. There were no new safety signals observed with up to 18 months of exposure at the described doses to idalopirdine.en_US
dc.language.isoenen_US
dc.publisherIOS Pressen_US
dc.relation.urlhttps://content.iospress.com/openurl?genre=article&id=doi:10.3233/JAD-180595en_US
dc.rightsCopyright ©2020 IOS Press All rights reserved.en_US
dc.subject5-HT6en_US
dc.subjectAlzheimer’s diseaseen_US
dc.subjectdementiaen_US
dc.subjectidalopirdineen_US
dc.subjecttreatmenten_US
dc.titleOpen-Label, Multicenter, Phase III Extension Study of Idalopirdine as Adjunctive to Donepezil for the Treatment of Mild-Moderate Alzheimer's Diseaseen_US
dc.typeClinical Trialen_US
dc.identifier.journalJournal of Alzheimer's Diseaseen_US
dc.type.versionPublisheden_US
dc.description.admin-notePublished version, accepted version, submitted versionen_US


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record